Abstract Next generation anti–CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumour-restricted activation. The goal is to achieve robust antitumour activity without inducing systemic immune-related toxicity.
Journal article
American Association for Cancer Research (AACR)
2026-06-08T00:00:00+00:00